NCT02076919View on ClinicalTrials.gov

First-in-Human Study of LHA510 in Elderly Subjects and Patients With Age-Related Macular Degeneration

PHASE1CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Age-Related Macular Degeneration
Interventions
DRUG

LHA510 Ophthalmic Suspension

Ophthalmic suspension in 4 concentration levels topically administered in Part 1 and Part 2

DRUG

LHA510 Vehicle

Inactive ingredients used for masking purposes

Sponsors

Lead Sponsor

Alcon Research
All Listed Sponsors
lead

Alcon Research

INDUSTRY